Samuel Bjork
Partner,
Digitalis Ventures
Samuel Bjork is a Partner at Digitalis Ventures, where he leads the firm's life sciences practice.
He has served as a director or observer on the boards of multiple companies, including Bonum Therapeutics, Elemental Machines, EpiBiologics, Good Therapeutics (acquired by Roche), Judo Bio, Nuvig Therapeutics, PetMedix (acquired by Zoetis), Switch Therapeutics, T-Therapeutics, and Terray Therapeutics, among others. Prior to Digitalis Ventures, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.
Sessions
-
10-Feb-2025AstorSecuring Your Next Funding Round: Industry Trends and Success Stories
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}